C
CytomX Therapeutics, Inc. (CTMX)
NMS – Real Time Price. Currency in USD
3.40
+0.13 (3.98%)
At close: Jun 26, 2026, 4:00 PM EDT
3.39
-0.01 (-0.29%)
After-hours: Jun 26, 2026, 6:36 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NMS – Real Time Price. Currency in USD
3.40
+0.13 (3.98%)
At close: Jun 26, 2026, 4:00 PM EDT
3.39
-0.01 (-0.29%)
After-hours: Jun 26, 2026, 6:36 PM EDT
No Data
There are no news for this stock.
Company's cash reserves $28.8M significantly exceed its total debt $2.9M, ensuring strong financial flexibility
Total current assets $353.1M exceed Total current liabilities $34.0M, highlighting excellent liquidity
Debt-to-equity ratio (0.0) is well below the industry average (0.3), showcasing prudent financial management
Interest expense exists but EBIT data is unavailable, indicating potential profitability concerns
Negative free cash flow -$25.5M limits the company's ability to reinvest or pay down debt
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Current ratio | 10.38 | 6.05 | 10 | |
| Quick ratio | 10.38 | 5.63 | 10 | |
| Debt to Equity | 0.01 | 0.30 | 10 | |
| Debt to Assets | 0.01 | 1.04 | 10 | |
| Interest coverage | N/A | -16.91 | 1.0 | |
| Weighted average score | 8.2 | |||
| METRIC | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Total Revenue | 53M | 101M | 138M | 76M | 36M |
| Gross Profit | 47M | 99M | 136M | 75M | 34M |
| Operating Income | -94M | -6M | 25M | -20M | -65M |
| Net Income | -99M | -569K | 32M | -17M | -59M |
| EBITDA | -88M | -4M | 27M | -18M | -64M |
| NAME | REVENUE GROWTH | EPS GROWTH | SCORE |
|---|---|---|---|
| Current quarter | -33.6 | N/A | 1.0 |
| Next quarter | 4.57 | -20.98 | 2.5 |
| Current year | -57.87 | -177.09 | 1.0 |
| Next year | 6.7 | -19.39 | 3.0 |
| Weighted average score | 1.9 | ||
| NAME | REVENUE | NET INCOME | EPS | FCF | SCORE |
|---|---|---|---|---|---|
| Q/Q | 1447.21 | 31.17 | 42.19 | -8.97 | 7.8 |
| Y/Y | -79.84 | -177.56 | -137.03 | -20.72 | 1.0 |
| 3y average | 27.34 | 1881.94 | 1286.63 | 3.24 | 8.5 |
| 5y average | 12.34 | 1081.55 | 752.13 | -834.6 | 7.0 |
| Weighted average score | 6.1 | ||||
Insufficient positive free cash flow for DCF analysis
| NAME | CURRENT | INDUSTRY | SCORE |
|---|---|---|---|
| Dividend yield | 0.00 | N/A | 1.0 |
| Payout ratio | 0.00 | N/A | 1.0 |
| 5-year dividend growth rate | N/A | N/A | 1.0 |
| Years of dividend increase | N/A | N/A | 1.0 |
| Weighted average score | 1.0 | ||
Insufficient positive free cash flow for DCF analysis
| NAME | SCALE | SCORE |
|---|---|---|
| Market share | None | 1.0 |
| Intangible assets | None | 1.0 |
| Switching costs | None | 1.0 |
| Network effect | None | 1.0 |
| Economies of scale | None | 1.0 |
| Weighted average score | 1.0 | |